.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the public market.The Eli Lilly-partnered biotech hopes to note on the Nasdaq under the symbol "BIOA," according to papers filed along with the Securities and Exchange Commission. The business has not openly shared an assumed financial volume for the offering.The clinical-stage business boasts lead prospect azelaprag, an orally supplied small particle slated to enter stage 2 screening in combo along with semaglutide-- sold through Novo Nordisk under trademark name Wegovy for fat loss-- in the initial half of following year. Semaglutide is actually likewise marketed as Ozempic and Rybelsus through Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is developed to mix properly with GLP-1 medicines, boosting weight management while keeping muscle mass. The investigational drug was located to become well-tolerated amongst 265 people around eight phase 1 tests, according to BioAge.Recently, BioAge amassed the assistance of Lilly to manage a test incorporating azelaprag with the Major Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetes as Mounjaro and also Zepbound for weight loss. The partners are actually currently conducting a phase 2 test of azelaprag and also tirzepatide, along with topline end results assumed in the third fourth of 2025.The biotech is actually additionally considering a blood insulin sensitiveness proof-of-concept test determining azelaprag as a monotherapy in the initial fifty percent of next year to sustain potential sign development. Furthermore, the provider prepares to talk to the FDA for approval in the 2nd half of 2025 to introduce human screening for an NLRP3 prevention targeting metabolic illness and also neuroinflammation.BioAge's anticipated relocate to the public market complies with a small uptick in organized biotech IPOs from Bicara Therapeutics and Zenas Biopharma. Zooming out, the latest IPO garden is actually a "blended picture," along with premium providers still debuting on everyone markets, only in decreased amounts, according to PitchBook.